Does Teriparatide Improve Femoral Neck Fracture Healing: Results From A Randomized Placebo-controlled Trial

This report has been verified by one or more authors of the original publication.

この研究はハイインパクトの可能性があります。 OEのAI駆動型ハイインパクト指標は、論文が掲載されたジャーナルと論文自体の科学的内容の両方からのシグナルを統合することで、論文が持つ可能性の高い影響力を推定します。 最先端の自然言語処理を用いて開発されたOEハイインパクトモデルは、ジャーナルのインパクトファクターのみよりも、研究の将来の引用実績をより正確に予測します。 これにより、臨床的に意義のある研究をより早く認識することが可能になり、読者は将来の診療を形成する可能性が最も高い論文に集中することができます。

161 men and postmenopausal women undergoing treatment with internal fixation for a unilateral femoral neck fracture resulting from a low-trauma event were randomized in two concurrent trials to receive either Teriparatide or a placebo once daily for 6 months. This study was conducted to determine if the benefits observed in revision rates, radiographic healing, and clinical outcomes with the use of Teriparatide in preclinical and preliminary clinical data were replicable in a hip fracture patients. Due to the slow accrual of patients enrollment was stopped early in these trials well before the planed sample size was reached. The analysis of the patients who were enrolled indicated that the use of Teriparatide did not provide a reduction in the risk of revision surgery, improve signs of radiographic healing, or decrease pain when compared to a placebo. These results should be interpreted with caution as the small sample size limited the power of this study to detect potential differences. Larger well designed randomized controlled trials are needed to further investigate the effects of Teriparatide in bone healing.